Dr. Reddy's Laboratories Ltd ADRDRREDDY
Price$12.25Intrinsic value$13.299% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $13.29median of 4 methods · middle span $13-$13based on filings through 31 Mar 2025
Market Price $12.25Price as of 1 Oct 2026
Margin of Safety +8.5%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 41.6% (near-term consensus, capped) · years 2–5: 3.7%/yr (balance of the path).10.4% per year
Years 6–10: glide to demonstrated growth own history 23.6%, capped at 20%
Per-year rates
Yr 65.0%Yr 76.4%Yr 87.7%Yr 99.0%Yr 1010.4%
3.7% → 10.4%
Years 11–20: glide to long-run rate
Per-year rates
Yr 119.6%Yr 128.9%Yr 138.1%Yr 147.4%Yr 156.7%Yr 165.9%Yr 175.2%Yr 184.5%Yr 193.7%Yr 203.0%
10.4% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)23.6%
Discount rate (cost of equity) 7.3%
Volatility vs market (adjusted beta)0.52

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetDr. Reddy's Laboratories Ltd ADRDRREDDYHealth Care
Valuation
P/E—
P/S2.7×
P/B2.6×
EV / Revenue2.6×
EV / EBITDA15.4×
Profitability
Gross margin52.8%
Operating margin15.0%
Net margin17.6%
FCF margin5.9%
Returns
ROE17.0%
ROA11.6%
ROIC17.4%
Growth
Revenue growth (YoY)13.8%
5-yr fwd EPS growth10.4%
Financial strength
Debt / Equity0.02×
Current ratio1.92×
Altman Z-Score—
Interest coverage—
Dividend yield0.7%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.